RemeGen Past Earnings Performance
Past criteria checks 0/6
RemeGen's earnings have been declining at an average annual rate of -28.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 44.5% per year.
Key information
-28.7%
Earnings growth rate
-15.7%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 44.5% |
Return on equity | -65.5% |
Net Margin | -102.0% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified
Sep 28RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price
Aug 20Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet
Jul 22Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet
Jun 21RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up
Apr 04Is RemeGen (HKG:9995) Using Debt In A Risky Way?
Mar 24RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Feb 18Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely
Dec 29RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate
Oct 16Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?
Aug 03Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?
Jun 22RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected
May 10Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?
Mar 09RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear
May 04RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially
Apr 08RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates
Feb 23We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely
Jan 21Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?
Nov 30We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely
Oct 16A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)
Aug 24Revenue & Expenses Breakdown
How RemeGen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1,522 | -1,552 | 1,162 | 1,602 |
30 Jun 24 | 1,402 | -1,588 | 1,111 | 1,572 |
31 Mar 24 | 1,245 | -1,536 | 1,119 | 1,388 |
31 Dec 23 | 1,083 | -1,511 | 1,087 | 1,306 |
30 Sep 23 | 972 | -1,341 | 1,059 | 1,178 |
30 Jun 23 | 844 | -1,213 | 973 | 1,073 |
31 Mar 23 | 790 | -1,036 | 821 | 1,014 |
31 Dec 22 | 772 | -999 | 718 | 982 |
30 Sep 22 | 1,879 | 276 | 642 | 849 |
30 Jun 22 | 1,745 | 231 | 582 | 834 |
31 Mar 22 | 1,570 | 174 | 543 | 793 |
31 Dec 21 | 1,424 | 276 | 483 | 711 |
30 Sep 21 | 115 | -912 | 378 | 663 |
30 Jun 21 | 29 | -892 | 338 | 604 |
31 Mar 21 | 4 | -783 | 291 | 527 |
31 Dec 20 | 0 | -698 | 242 | 466 |
30 Sep 20 | 0 | -588 | 175 | 423 |
30 Jun 20 | 0 | -478 | 109 | 380 |
31 Mar 20 | 0 | -442 | 84 | 358 |
31 Dec 19 | 0 | -430 | 69 | 352 |
31 Dec 18 | 11 | -270 | 29 | 216 |
Quality Earnings: 9995 is currently unprofitable.
Growing Profit Margin: 9995 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9995 is unprofitable, and losses have increased over the past 5 years at a rate of 28.7% per year.
Accelerating Growth: Unable to compare 9995's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9995 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.4%).
Return on Equity
High ROE: 9995 has a negative Return on Equity (-65.52%), as it is currently unprofitable.